Home > Insider Trading > Filing (0000950170-25-037880)

Filing Details

Accession Number:: 0000950170-25-037880
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-03-12 16:00:04
Reporting Period:: 2025-03-10

Filing Date:: 2025-03-12
Accepted Time:: 2025-03-12 16:00:04
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1563880	Trevi Therapeutics Inc.	TRVI	Pharmaceutical Preparations (2834)	450834299

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1965585	Farrell Simon	C/O Trevi Therapeutics, Inc. 195 Church Street, 16Th Floor New Haven CT 06510	Chief Commercial Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2025-03-10	17,500	$3.21	63,150	No	4	M	Direct
Common Stock	Acquisiton	2025-03-10	63,813	$3.91	126,963	No	4	M	Direct
Common Stock	Acquisiton	2025-03-10	31,250	$0.51	158,213	No	4	M	Direct
Common Stock	Disposition	2025-03-10	76,963	$6.73	81,250	No	4	S	Direct
Common Stock	Disposition	2025-03-10	4,350	$7.15	76,900	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Performance Stock Option (right to buy)	Acquisiton	2025-03-10	38,400	$0.00	38,400	$2.38
Common Stock	Performance Stock Option (right to buy)	Disposition	2025-03-10	17,500	$0.00	17,500	$3.21
Common Stock	Stock Option (right to buy)	Disposition	2025-03-10	63,813	$0.00	63,813	$3.91
Common Stock	Stock Option (right to buy)	Disposition	2025-03-10	31,250	$0.00	31,250	$0.51

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
38,400	2025-03-10	2034-02-14	No	4	A	Direct
0		2031-02-16	No	4	M	Direct
11,187		2030-09-22	No	4	M	Direct
18,750		2032-02-10	No	4	M	Direct

Footnotes

This exercise of stock options was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024.
This sale was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.14 to $7.13 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.14 to $7.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 120,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 38,400 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied.
Reporting person was granted a performance-based stock option on February 17, 2021, to purchase 17,500 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b/3 PRISM trial of Haduvio for the treatment of prurigo nodularis, and Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis.
This option was granted on September 22, 2020. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on September 22, 2021 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through September 22, 2024.
This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.